Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer

Part of paid clinical trials in New York, New York.

Sponsor: NYU Langone Health
Study ID: NCT07801664
Phase: PHASE2
Status: Recruiting

Apply to this trial

Conditions

Prostate Cancer

Eligibility Criteria

Sex: MALE
Age: 18 Years - N/A
Healthy Volunteers: Not accepted

Interventions

Androgen Deprivation Therapy (ADT) — DRUG
ADT will be delivered with monthly Degarelix, or Leuprolide injections or daily Relugolix pills which are all standard ADT interventions.
Radiotherapy — RADIATION
Dose-escalated radiotherapy.

Study Details

For this study, high risk prostate cancer patients with lower risk ARTERA scores will be treated with 6 months of Androgen Deprivation Therapy (ADT) in conjunction with dose escalated radiotherapy to the prostate and nodes. Specifically, patients enrolled in this study will undergo one of several dose-escalated forms of radiotherapy which would include SBRT with or without a brachytherapy boost.

Key Dates

First listed: Sep 3, 2026
Start date: Aug 6, 2026
Status verified: Aug 2026
Primary completion: Aug 1, 2028
Completion: Aug 1, 2029

Study Design

Enrollment: 90 participants (estimated)
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Arms

Experimental: High-Risk Prostate Cancer Patients with Lower-Risk ARTERA Scores
Patients will be treated with 6 months of Androgen Deprivation Therapy (ADT) in conjunction with dose escalated radiotherapy to the prostate and nodes.